IAG, Image Analyis Group will present 5 abstracts at the virtual European League Against Rheumatism (EULAR)
IAG, Image Analysis Group, a strategic clinical development partner to Life Sciences companies, announces that 5 abstracts by IAG’s scientific leadership, academic collaborators and biotech and pharma partners will be presented during this year’s virtual European League Against Rheumatism, EULAR 2020.
The publications are based upon the data collected and analyzed in IAG’s latest clinical research studies.
They outline the benefit of deployment of advanced imaging and computer-aided methodologies to provide accurate quantitative assessment of treatment response in clinical trials for rheumatic diseases.
Therapeutic Areas: Rheumatoid Arthritis, Lupus Nephratis, Psoriatic Arthritis, Systemic Sclerosis,
The accepted abstracts and posters are:
Title: “Novel Computer-Assisted Methodology for Quantitative Assessment of MRI Treatment Responses to Apremilast in Patients with Psoriatic Arthritis.”
Presenter: Dr. Olga Kubassova, IAG’s CEO
Industry Partner: Amgen
Title: “Optimal Use of Contrast Enhanced MRI for Clinical Trials of Inflammatory Diseases: Retrospective Analysis of Data from a Phase IIb Study of Baricitinib in Patients with Active Rheumatoid Arthritis.”
Presenter: Prof. Mikael Boesen, IAG’s Head of Musculoskeletal Imaging Research
Industry Partner: Eli Lilly
Title: “Digital Artery Volume Index (DAVIX©) Predicts the Onset of Future Digital Ulcers in Patients with Systemic Sclerosis.”
Presenter: Dr. Francesco Del Galdo, Associate Professor at the University of Leeds
Academic Partner: University of Leeds, UK
Title: “Multi-Modality Imaging to Evaluate Lupus Nephritis.”
Presenter: Dr. Peter Lipsky
Industry Partner: Relite, AMPEL BioSolutions
Title: “Efficacy and Safety of the Prostaglandin EP4 Receptor Antagonist CR6086 Added to Methotrexate in DMARD-Naïve Early RA Patients: a Phase 2 Randomized Controlled Trial.”
Presenter: Prof. Peter C. Taylor
Industry Partner: Rottapharm Biotech, Musculoskeletal Sciences at the University of Oxford
Full publication released by EULAR on June 3, 2020, at 00:01 AM CET on www.congress.eular.org
To receive an abstract or to speak to our experts please email: firstname.lastname@example.org
is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development.
If you are interested in meeting our expert team at EULAR’20 Virtual Conference please email <email@example.com>